Downstream Processing

of Recombinant Human Insulin

and Its Analogues Production from E.
coli Inclusion bodies

* rodu
Ria Ceriana
Introduction
Diabetes is a global epidemic (WHO 2021).

More than 420 million (6% of the world’s population)

were living with diabetes before COVID-19 emerged,
and it is predicted that this number would surge to
500 million by 2030, and to 700 million by 2045 (WHO
2021).

Te rise in the number of diabetics worldwide would

lead to the consequential increase in the demand for
insulin.
Using E. coli as the expression system for large-scale
recombinant insulin production possesses the
advantages of high growth rate, simple media
requirement, ease of handling, high yield, and cost
efectiveness.
 *Conclusions
Insulin is a scarce commodity, with global demands
projected to rise due to increasing prevalence of diabetes.
The chronic nature of diabetes means that patients require
long-term insulin treatment, and this can place heavy
financial burden on the healthcare systems and individuals.
It is therefore imperative that all the manufacturers and
stakeholders continue to play their parts in making further
progresses in therapeutic recombinant insulin development
and production.